Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007547 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Minimally Invasive Surfactant Evaluation
A Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn, sponsored by Endeavor Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06007547: Recruiting Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn, sponsored by Endeavor Health.
NCT06007547 is a Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 200 participants, below the 389-participant average among 38 other Premature Birth trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06007547, a Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn, is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
Primary Outcome
Oxygen requirement \> 45% requiring endotracheal intubation
Conditions Studied
Interventions
- DRUG Poractant Alfa
Study Locations (1)
Illinois
- Northshore University Healthsystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 4 |
What NCT06007547 shows while recruiting
NCT06007547 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 38 other Premature Birth trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Premature Birth appearing as the primary indexed condition, and to 1 intervention - of which Poractant Alfa is the first listed.
NCT06007547 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06007547 about?
NCT06007547 is a clinical study titled "Prophylactic Minimally Invasive Surfactant Evaluation". The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
What is the current status of trial NCT06007547?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2024-01-01. Estimated completion is 2027-07-31.
What conditions does trial NCT06007547 study?
This clinical trial studies the following conditions: Premature Birth, Respiratory Distress Syndrome, Newborn.
What interventions are being tested in trial NCT06007547?
The interventions under investigation include: Poractant Alfa (DRUG).
Who is sponsoring clinical trial NCT06007547?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007547 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Birth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06007547's enrollment target sits among peer trials
200 14th of 38 higher than 25 of 38 other Premature Birth trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Premature Birth trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age
RECRUITING · Phase 4
-
A Randomized Controlled Trial of Impact of Wearable, Wireless Breast Pumps on Frequency and Efficacy of Milk Expression in Mothers of Premature Infants
RECRUITING · NA
-
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
RECRUITING · NA
-
The Periviable GOALS Decision Support Tool
RECRUITING · NA
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
-
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI